Evonik expanded its EUDRACAP portfolio with a new functional, ready-to-fill capsule that enables the delivery of sensitive active ingredients to the ileo-colonic region. EUDRACAP colon has been designed to meet the need for a capsule that can deliver sensitive active ingredients, such as live biotherapeutic products (LBPs) to treat or prevent a wide range of diseases, to the ileo-colonic region. It’s currently available in technical grade with a GMP-grade product in development. EUDRACAP functional capsules aim to help streamline the development of oral drugs, reducing complexity in formulation.
 
The EUDRACAP platform leverages EUDRAGIT coatings for tailored oral drug release to meet specific customer needs.
 
“Drawing on decades of know-how, we are working with customers on new paths for ileo-colonic delivery. Our EUDRACAP® platform is a testament to strong innovation and growth and we are delighted to expand this portfolio,” said Axel Schroeder, Head of Oral Drug Delivery Solutions at Evonik.
 
EUDRACAP colon can be used for the delivery of sensitive active ingredients such as live biotherapeutics, oral biologics, proteins, peptides and nucleotides (RNA). These actives are used in the formulation of drugs for the treatment of conditions such as obesity, HIV, or Cystic Fibrosis, as well as for local delivery such as for colorectal cancer and infections.
 
Evonik provides CDMO services for customer requirements including a range of sizes, colors, and customized release profiles.